Applications of nanotechnology in vaccine delivery

International Journal of Green Nanotechnology: Biomedicine

Volumn 2, Issue 1, 2010, Pages

  Singh, Abhalaxmi ^a   Misra, Ranjita ^a   Mohanty, Chandana ^a   Sahoo, Sanjeeb K ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Antigen presenting cells; Antigens; Dendritic cells; Immunogenicity; Microparticles; Nanoparticles; Vaccine delivery system

Indexed keywords

ANTIGEN; CALCIUM CHLORIDE; CALCIUM ION; CALCIUM PHOSPHATE; CANCER VACCINE; CITRATE SODIUM; DENDRIMER; HEMAGGLUTININ; HEPATITIS B VACCINE; HEPATITIS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; ISCOM; LEUPRORELIN; LIPOPOLYSACCHARIDE; LIPOSOME; MALARIA VACCINE; MEASLES VACCINE; MURAMYL PEPTIDE; NANOPARTICLE; PHOSPHORYL LIPID A; POLYGLACTIN; POLYLACTIC ACID; RISPERIDONE; STIMUVAX; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; VIRUS GLYCOPROTEIN;

ANTIGEN PRESENTATION; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CLINICAL TRIAL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG TARGETING; EMULSION; ENCAPSULATION; GENE DELIVERY SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INJECTION; LUNG NON SMALL CELL CANCER; MICELLE; MICROPARTICLE ENZYME IMMUNOASSAY; MOLECULAR WEIGHT; MUCOSAL IMMUNITY; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; VACCINATION;

EID: 77958516482     PISSN: 1943085X     EISSN: 19430906     Source Type: Journal    
DOI: 10.1080/1943085x.2010.488198     Document Type: Article

References (148)

1. Rappuoli, R.; Miller, H. I.; Falkow, S. Medicine. The intangible value of vaccination. Science 2002, 297, 937-939.
2. Klein, M. Prospects and challenges for prophylactic and therapeutic HIV vaccines. Vaccine 2003, 21, 616-619.
3. Sally, B.; Ronald, B. M.; Eduardo, F. C. Calculating the potential epidemic-level impact of therapeutic vaccination on the San Fransisco HIV epidemic. AIDScience 2003,3.
4. Vaccine Introduction Guidelines: Adding a Vaccines to National Immunization Programme: Decision and Implementation. www.who.int/vaccines-documents, 2005.
5. Plotkin, S. L.; Plotkin, S. A. Vaccines; WB Saunders Company: Philadelphia, 2004.
6. Goldsby, R. A.; Kindt, T. J.; Osborne, B. A. Kuby Immunology; W. H. Freeman: San Francisco, 2008.
7. Peek, L. J.; Middaugh, C. R.; Berkland, C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev. 2008, 60, 915-928.
8. Kamath, A. T.; Feng, C. G.; Macdonald, M.; Briscoe, H.; Britton, W. J. Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect. Immun. 1999, 67, 1702-1707.
9. Jin, H.; Xiao, C.; Chen, Z.; Kang, Y.; Ma, Y.; Zhu, K.; Xie, Q.; Tu, Y.; Yu, Y.; Wang, B. Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. Biochem. Biophys. Res. Commun. 2005, 328, 979-986.
10. Burgers, W. A.; van Harmelen, J. H.; Shephard, E.; Adams, C.; Mgwebi, T.; Bourn, W.; Hanke, T.; Williamson, A. L.; Williamson, C. Design and preclinical evaluation of a multigene human immunodeficiency virus type 1 subtype C DNA vaccine for clinical trial. J. Gen. Virol. 2006, 87, 399-410.
11. Kohli, A. K.; Alpar, H. O. Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge. Int. J. Pharm. 2004, 275, 13-17.
12. Giudice, E. L.; Campbell, J. D. Needle-free vaccine delivery. Adv. Drug Deliv. Rev. 2006, 58, 68-89.
13. Boyle, J. S.; Brady, J. L.; Lew, A. M. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 1998, 392, 408-411.
14. Lu, W.; Wu, X.; Lu, Y.; Guo, W.; Andrieu, J. M. Therapeutic dendritic-cell vaccine for simian AIDS. Nat. Med. 2003, 9, 27-32.
15. Neundorf, I.; Rennert, R.; Franke, J.; Kozle, I.; Bergmann, R. Detailed analysis concerning the biodistribution and metabolism of human calcitonin-derived cellpenetrating peptides. Bioconjug. Chem. 2008, 19, 1596-1603.
16. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2, 347-360.
17. Gursoy, R. N.; Benita, S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother. 2004, 58, 173-182.
18. Putnam, D. Polymers for gene delivery across length scales. Nat. Mater. 2006, 5, 439-451.
19. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4, 145-160.
20. Kommareddy, S.; Tiwari, S. B.; Amiji, M. M. Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technol. Cancer Res. Treat. 2005, 4, 615-625.
21. Koping-Hoggard, M.; Sanchez, A.; Alonso, M. J. Nanoparticles as carriers for nasal vaccine delivery. Expert Rev. Vaccines 2005, 4, 185-196.
22. Tiwari, S. B.; Amiji, M. M. A review of nanocarrier-based CNS delivery systems. Curr. Drug Deliv. 2006, 3, 219-232.
23. Borges, O.; Silva, M.; de Sousa, A.; Borchard, G.; Junginger, H. E.; Cordeiro-da-Silva, A. Alginate coated chitosan nanoparticles are an effective subcutaneous adjuvant for hepatitis B surface antigen. Int. Immunopharmacol. 2008,8,1773-1780.
24. Csaba, N.; Garcia-Fuentes, M.; Alonso, M. J. Nanoparticles for nasal vaccination. Adv. Drug Deliv. Rev. 2009,61,140-157.
25. Sahoo, S. K.; Parveen, S.; Panda, J. J. The present and future of nanotechnology in human health care. Nanomedicine 2007, 3, 20-31.
26. Shahiwala, A.; Vyas, T. K.; Amiji, M. M. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat. Drug Deliv. Formul. 2007, 1, 1-9.
27. Griffiths, G. D.; Bailey, S. C.; Hambrook, J. L.; Keyte, M.; Jayasekera, P.; Miles, J.; Williamson, E. Liposomally-encapsulated ricin toxoid vaccine delivered intratracheally elicits a good immune response and protects against a lethal pulmonary dose of ricin toxin. Vaccine 1997,15,1933-1939.
28. Banchereau, J.; Steinman, R. M. Dendritic cells and the control of immunity. Nature 1998, 392, 245-252.
29. Gamvrellis, A.; Leong, D.; Hanley, J. C.; Xiang, S. D.; Mottram, P.; Plebanski, M. Vaccines that facilitate antigen entry into dendritic cells. Immunol. Cell. Biol.2004, 82,506-516.
30. Gupta, R. K.; Rost, B. E.; Relyveld, E.; Siber, G. R. Adjuvant properties of aluminum and calcium compounds. Pharm. Biotechnol. 1995, 6, 229-248.
31. Mohanty, C.; Arya, G.; Verma, R. S.; Sahoo, S. K. Nanobiotechnology: application of nanotechnology in therapeutics and diagnosis. Int. J. Green Nanotechnol. Biomed. 2009,1, B24-B38.
32. Nasir, A. Nanotechnology in vaccine development: a step forward. J. Invest. Dermatol. 2009, 129, 1055-1059.
33. Abbas, A. O.; Donovan, M. D.; Salem, A. K. Formulating poly(lactide-co-glycolide) particles for plasmid DNA delivery. J. Pharm. Sci. 2008, 97, 2448-2461.
34. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55, 329-347.
35. Illum, L. Nanoparticulate systems for nasal delivery of drugs: a real improvement over simple systems? J. Pharm. Sci. 2007, 96, 473-483.
36. Okada, J.; Cohen, S.; Langer, R. S. US576294, 1998.
37. Langer, R. S.; Chen, H. US6004534, 1999.
38. Alving, C. R. Liposomes as carriers of antigens and adjuvants. J. Immunol. Methods 1991, 140, 1-13.
39. Alving, C. R.; Banerji, B.; Shiba, T.; Kotani, S.; Clements, J. D.; Richards, R. L. Liposomes as vehicles for vaccines. Prog. Clin. Biol. Res. 1980, 47, 339-355.
40. Saupe, A.; McBurney, W.; Rades, T.; Hook, S. Immuno stimulatory colloidal delivery systems for cancer vaccines. Expert Opin. Drug Deliv. 2006, 3, 345-354.
41. Parr, M. J.; Ansell, S. M.; Choi, L. S.; Cullis, P. R. Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated into large unilamellar vesicles. Biochim. Biophys. Acta 1994, 1195,21-30.
42. van Wijk, G. M.; Gadella, T. W.; Wirtz, K. W.; Hostetler, K. Y.; van den Bosch, H. Spontaneous and protein-mediated intermembrane transfer of the antiretroviral liponucleotide 3'-deoxythymidine diphosphate diglyceride. Biochemistry 1992, 31, 5912-5917.
43. Clark, M. A.; Blair, H.; Liang, L.; Brey, R. N.; Brayden, D.; Hirst, B. H. Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 2001, 20, 208-217.
44. Nakanishi, T.; Kunisawa, J.; Hayashi, A.; Tsutsumi, Y.; Kubo, K.; Nakagawa, S.; Nakanishi, M.; Tanaka, K.; Mayumi, T. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J. Control. Release 1999, 61, 233-240.
45. de Haan, A.; Tomeea, J. F.C.; Huchshorn, J. P.; Wilschut, J. Liposomes as an immunoadjuvant system for stimulation of mucosal and systemic antibody responses against inactivated measles virus administered intranasally to mice. Vaccine 1995, 13, 1320-1324.
46. Guan, H. H.; Budzynski, W.; Koganty, R. R.; Krantz, M. J.; Reddish, M. A.; Rogers, J. A.; Longenecker, B. M.; Samuel, J. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug. Chem. 1998, 9, 451-458.
47. Choi, C. New vaccine against the deadliest of all cancers teaches the body to defend itself while avoiding the side effects of more traditional therapies. Scientific American Special Report, 2006.
48. Butts, C.; Murray, N.; Maksymiuk, A.; Goss, G.; Marshall, E.; Soulieres, D.; Cormier, Y.; Ellis, P.; Price, A.; Sawhney, R.; Davis, M.; Mansi, J.; Smith, C.; Vergidis, D.; Ellis, P.; MacNeil, M.; Palmer, M. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 2005, 23, 6674-6681.
49. Palmer, M.; Parker, J.; Modi, S.; Butts, C.; Smylie, M.; Meikle, A.; Kehoe, M.; MacLean, G.; Longenecker, M. Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin. Lung Cancer 2001, 3, 49-57; discussion 58.
50. Mougin, B.; Bakouche, O.; Gerlier, D. Humoral immune response elicited in rats by measles viral membrane antigens presented in liposomes and ISCOMs. Vaccine 1988,6,445-449.
51. Garnier, F.; Forquet, F.; Bertolino, P.; Gerlier, D. Enhancement of in vivo and in vitro T cell response against measles virus haemagglutinin after its incorporation into liposomes: effect of the phospholipid composition. Vaccine 1991,9,340-345.
52. Kreuter, J. Nanoparticles and microparticles for drug and vaccine delivery. J. Anat. 1996, 189(Pt 3), 503-505.
53. Cappel, M. J.; Kreuter, J. Effect of nanoparticles on transdermal drug delivery. J. Microencapsul. 1991, 8, 369-374.
54. Kreuter, J. Nanoparticles in Colloidal Drug Delivery Systems; Marcel Dekker: New York, 1994.
55. Bala, I.; Hariharan, S.; Kumar, M. N. PLGA nanoparticles in drug delivery: the state of the art. Crit. Rev. Ther. Drug Carrier Syst. 2004, 21, 387-422.
56. Ueda, H.; Hariharan, S.; Kumar, M. N. Polyhydroxy alkanonate derivative in current clinical applications and trials. Adv. Drug Deliv. Rev. 2003, 55, 501-518.
57. Fischer, S.; Uetz-von Allmen, E.; Waeckerle-Men, Y.; Groettrup, M.; Merkle, H. P.; Gander, B. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 2007, 28, 994-1004.
58. Jiang, W.; Gupta, R. K.; Deshpande, M. C.; Schwendeman, S. P. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliv. Rev. 2005, 57, 391-410.
59. Tamber, H.; Johansen, P.; Merkle, H. P.; Gander, B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Deliv. Rev. 2005, 57,357-376.
60. van de Weert, M.; Hennink, W. E.; Jiskoot, W. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. 2000, 17, 1159-1167.
61. Akagi, T.; Wang, X.; Uto, T.; Baba, M.; Akashi, M. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 2007, 28, 3427-3436.
62. Akashi, M.; Akagi, T.; Nakagawa, S.; Baba, M. Biodegradable nanoparticles for vaccine delivery and adjuvant Swiss-Japan Symposium on Nanobio, October 10-11, 2007.
63. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y. J.; Preat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 2006, 116, 1-27.
64. Jung, T.; Kamm, W.; Breitenbach, A.; Hungerer, K. D.; Hundt, E.; Kissel, T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm. Res. 2001,18,352-360.
65. Avnir, D.; Braun, S.; Lev, O.; Ottolenghi, M. Enzymes and other proteins entrapped in Sol-Gel materilas. Chem. Mater. 1994, 6, 1605-1614.
66. Jain, T. K.; Roy, I.; De, T. K.; Maitra, A. N. Nanometer silica particles encapsulating active compounds: a novel ceramic drug carrier. J. Am. Chem. Soc. 1998, 120, 11092-11095.
67. Ochekpe, N. A.; Olorunfemi, P. O.; Ngwuluka, N. C. Nanotechnology and drug delivery. Part 2: Nanostructures for drug delivery. Trop. J. Pharm. Res. 2009, 3, 275-287.
68. Kneuer, C.; Sameti, M.; Bakowsky, U.; Schiestel, T.; Schirra, H.; Schmidt, H.; Lehr, C. M. A nonviral DNA delivery system based on surface modified silica-nanoparticles can efficiently transfect cells in vitro. Bioconjug. Chem. 2000,11,926-932.
69. Luo, D.; Saltzman, W. M. Enhancement of transfection by physical concentration of DNA at the cell surface. Nat. Biotechnol. 2000, 18, 893-895.
70. Tischer, B. K.; Schumacher, D.; Beer, M.; Beyer, J.; Teifke, J. P.; Osterrieder, K.; Wink, K.; Zelnik, V.; Fehler, F.; Osterrieder, N. A DNA vaccine containing an infectious Marek's disease virus genome can confer protection against tumorigenic Marek's disease in chickens. J. Gen. Virol. 2002,83,2367-2376.
71. Zhang, L.; Widera, G.; Bleecher, S.; Zaharoff, D. A.; Mossop, B.; Rabussay, D. Accelerated immune response to DNA vaccines. DNA Cell. Biol. 2003, 22, 815-822.
72. Zhang, L.; Widera, G.; Rabussay, D. Enhancement of the effectiveness of electroporation-augmented cutaneous DNA vaccination by a particulate adjuvant. Bioelectrochemistry 2004, 63, 369-373.
73. Patil, S. D.; Rhodes, D. G.; Burgess, D. J. DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J. 2005, 7, E61-77.
74. Mahvi, D. M.; Shi, F. S.; Yang, N. S.; Weber, S.; Hank, J.; Albertini, M.; Schiller, J.; Schalch, H.; Larson, M.; Pharo, L.; Gan, J.; Heisey, D.; Warner, T.; Sondel, P. M. Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: report of a phase I/IB study. Hum. Gene Ther. 2002, 13,1711-1721.
75. Fuller, D. H.; Loudon, P.; Schmaljohn, C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006, 40, 86-97.
76. Fynan, E. F.; Webster, R. G.; Fuller, D. H.; Haynes, J. R.; Santoro, J. C.; Robinson, H. L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 11478-11482.
77. Luo, D.; Saltzman, W. M. Synthetic DNA delivery systems. Nat. Biotechnol. 2000, 18, 33-37.
78. Copland, M. J.; Rades, T.; Davies, N. M.; Baird, M. A. Lipid based particulate formulations for the delivery of antigen. Immunol. Cell. Biol. 2005, 83, 97-105.
79. Bhakta, G.; Mitra, S.; Maitra, A. DNA encapsulated magnesium and manganous phosphate nanoparticles: potential non-viral vectors for gene delivery. Biomaterials 2005,26,2157-2163.
80. He, Q.; Mitchell, A.; Morcol, T.; Bell, S. J. Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2. Clin. Diagn. Lab. Immunol. 2002, 9, 1021-1024.
81. He, Q.; Mitchell, A. R.; Johnson, S. L.; Wagner-Bartak, C.; Morcol, T.; Bell, S. J. Calcium phosphate nanoparticle adjuvant. Clin. Diagn. Lab. Immunol. 2000, 7,899-903.
82. Goto, N.; Kato, H.; Maeyama, J.; Eto, K.; Yoshihara, S. Studies on the toxicities of aluminium hydroxide and calcium phosphate as immunological adjuvants for vaccines. Vaccine 1993, 11, 914-918.
83. BioSante Pharmaceuticals. Calcium Phosphate Nanoparticles (CAP), 2007.
84. Joyappa, D. H.; Ashok Kumar, C.; Banumathi, N.; Reddy, G. R.; Suryanarayana, V. V. Calcium phosphate nanoparticle prepared with foot and mouth disease virus P1-3CD gene construct protects mice and guinea pigs against the challenge virus. Vet. Microbiol. 2009, 139(1-2), 58-66.
85. Boas, U.; Heegaard, P. M. Dendrimers in drug research. Chem Soc Rev 2004, 33, 43-63.
86. Frechet, J. M. J.; Tornalia, D. Dendrimers and Other Dentritic Polymers; John Wiley & Sons: New York, 2001.
87. Ribeiro, S.; Rijpkema, S. G.; Durrani, Z.; Florence, A. T. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. Int. J. Pharm. 2007, 331, 228-232.
88. Newkome, G. R. Dendrimers and Dendrons: Concepts, Synthesis Applications; Wiley-VCH: Weinheim, 2001.
89. Haensler, J.; Szoka, F. C., Jr. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug. Chem. 1993, 4, 372-379.
90. Aulenta, F.; Hayes, W.; Rannard, S. Dendrimers: a new class of nanoscopic containers and delivery devices. Eur. Polym. J. 2003, 39, 1741-1771.
91. Esfand, R.; Tomalia, D. A. Poly(amidoamine) (PA-MAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today 2001, 6, 427-436.
92. Svenson, S.; Tomalia, D. A. Dendrimers in biomedical applications-reflections on the field. Adv. Drug Deliv. Rev. 2005, 57, 2106-2129.
93. Tam, J. P. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. U. S. A. 1988, 85, 5409-5413.
94. Wang, R.; Charoenvit, Y.; Corradin, G.; Porrozzi, R.; Hunter, R. L.; Glenn, G.; Alving, C. R.; Church, P.; Hoffman, S. L. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. J. Immunol. 1995, 154,2784-2793.
95. Sadler, K.; Tam, J. P. Peptide dendrimers: applications and synthesis. J. Biotechnol. 2002, 90, 195-229.
96. Moreno, C. A.; Rodrigues, R.; Oliveira, G. A.; Ferreira, V.; Nussenzweig, R. S.; Moya Castro, Z. R.; Calvo-Calle, J. M.; Nardin, E. Preclinical evaluation of a synthetic. Plasmodium falciparum MAP malaria vaccine in Aotus monkeys and mice: Vaccine 1999, 18(1-2), 89-99.
97. Ota, S.; Ono, T.; Morita, A.; Uenaka, A.; Harada, M.; Nakayama, E. Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic T lymphocytes on antigen-presenting cells. Cancer Res. 2002, 62, 1471-1476.
98. Rajanathanan, P.; Sheikh, N. A.; Attard, G. S.; Morrow, W. J.W. Evaluation of novel aggregate structures as adjuvants; composition, toxicity studies and humoral responses. Vaccine 1999, 17, 715-730.
99. Wright, D. C. US5795582, 1998.
100. Sheng, K. C.; Kalkanidis, M.; Pouniotis, D. S.; Esparon, S.; Tang, C. K.; Apostolopoulos, V.; Pietersz, G. A. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur. J. Immunol. 2008, 38, 424-436.
101. Misumi, S.; Masuyama, M.; Takamune, N.; Nakayama, D.; Mitsumata, R.; Matsumoto, H.; Urata, N.; Takahashi, Y.; Muneoka, A.; Sukamoto, T.; Fukuzaki, K.; Shoji, S. Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer. J. Immunol. 2009, 182,6061-6070.
102. Jones, M.; Leroux, J. Polymeric micelles-a new generation of colloidal drug carriers. Eur. J. Pharm. Biopharm. 1999, 48, 101-111.
103. Scheerlinck, J. P.; Greenwood, D. L. Virus-sized vaccine delivery systems. Drug Discov. Today 2008, 13, 882-887.
104. Lenarczyk, A.; Le, T. T.; Drane, D.; Malliaros, J.; Pearse, M.; Hamilton, R.; Cox, J.; Luft, T.; Gardner, J.; Suhrbier, A. ISCOM based vaccines for cancer immunotherapy. Vaccine 2004, 22, 963-974.
105. Mowat, A. M. Dendritic cells and immune responses to orally administered antigens. Vaccine 2005, 23, 1797-1799.
106. Pearse, M. J.; Drane, D. ISCOMATRIX adjuvant for antigen delivery. Adv. Drug Deliv. Rev. 2005, 57, 465-474.
107. Cox, J. C.; Sjolander, A.; Barr, I. G. ISCOMs and other saponin based adjuvants. Adv. Drug Deliv. Rev. 1998, 32,247-271.
108. Frazer, I.H.; Quinn, M.; Nicklin, J.L.; Tan, J.; Perrin, L. C.; Ng, P.; O'Connor, V. M.; White, O.; Wendt, N.; Martin, J.; Crowley, J. M.; Edwards, S. J.; McKenzie, A. W.; Mitchell, S. V.; Maher, D. W.; Pearse, M. J.; Basser, R. L. Phase 1 study of HPV16-specific immunotherapy with E6E7fusionproteinandISCOMATRIXadjuvantinwomen with cervical intraepithelial neoplasia. Vaccine 2004, 23, 172-181.
109. Davis, I. D.; Chen, W.; Jackson, H.; Parente, P.; Shackleton, M.; Hopkins, W.; Chen, Q.; Dimopoulos, N.; Luke, T.; Murphy, R.; Scott, A. M.; Maraskovsky, E.; McArthur, G.; MacGregor, D.; Sturrock, S.; Tai, T. Y.; Green, S.; Cuthbertson, A.; Maher, D.; Miloradovic, L.; Mitchell, S. V.; Ritter, G.; Jungbluth, A. A.; Chen, Y. T.; Gnjatic, S.; Hoffman, E. W.; Old, L. J.; Cebon, J. S. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc. Natl. Acad. Sci. U. S. A. 2004,101,10697-10702.
110. Rimmelzwaan, G.F.; Baars, M.; vanAmerongen, G.; van Beek, R.; Osterhaus, A. D. A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine 2001, 20, 158-163.
111. Hu, K. F.; Lovgren-Bengtsson, K.; Morein, B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug Deliv. Rev. 2001, 51, 149-159.
112. Coulter, A.; Harris, R.; Davis, R.; Drane, D.; Cox, J.; Ryan, D.; Sutton, P.; Rockman, S.; Pearse, M. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 2003, 21, 946-949.
113. Thapar, M. A.; Parr, E. L.; Bozzola, J. J.; Parr, M. B. Secretory immune responses in the mouse vagina after parenteral or intravaginal immunization with an immuno stimulating complex(ISCOM).Vaccine 1991,9,129-133.
114. Pinitkiatisakul, S.; Friedman, M.; Wikman, M.; Mattsson, J. G.; Lovgren-Bengtsson, K.; Stahl, S.; Lunden, A. Immunogenicity and protective effect against murine cerebral neosporosis of recombinant NcSRS2 in different iscom formulations. Vaccine 2007, 25, 3658-3668.
115. Coombes, A. G.; Lavelle, E. C.; Jenkins, P. G.; Davis, S. S. Single dose, polymeric, microparticle-based vaccines: the influence of formulation conditions on the magnitude and duration of the immune response to a protein antigen. Vaccine 1996, 14, 1429-1438.
116. McDermott, M. R.; Heritage, P. L.; Bartzoka, V.; Brook, M. A. Polymer-grafted starch microparticles for oral and nasal immunization. Immunol. Cell. Biol. 1998, 76,256-262.
117. Alpar, H. O.; Ward, K. R.; Williamson, E. D. New strategies in vaccine delivery. S. T. P. Pharma Sci. 2000, 10,269-278.
118. Barackman, J. D.; Singh, M.; Ugozolli, M.; S., O. G.; O'Hagan, D. T. Oral immunization with poly(lactide-co-glycolide) microparticles containing an entrapped recombinant glycoprotein (gD2) from Herpes simplex type 2 virus. S. T. P. Pharma Sci. 1998, 8, 41-46.
119. van der Lubben, I. M.; Kersten, G.; Fretz, M. M.; Beuvery, C.; Verhoefa, J. C.; Junginger, H. E. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice Vaccine 2002, 21, 1400-1408.
120. Eldridge, C. H.; Hammond, C. J.; Meulbroek, J. A.; Staas, J. K.; Gilley, R. M.; Rice, T. R. Controlled vaccine release in the gut associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J. Control. Release 1990, 11, 205-214.
121. Eldridge, J. H.; Staas, J. K.; Meulbroek, J. A.; Tice, T. R.; Gilley, R. M. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 1991,59,2978-2986.
122. Audran, R.; Peter, K.; Dannull, J.; Men, Y.; Scandella, E.; Groettrup, M.; Gander, B.; Corradin, G. Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro. Vaccine 2003, 21, 1250-1255.
123. Johansen, P.; Men, Y.; Merkle, H. P.; Gander, B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur. J. Pharm. Biopharm. 2000,50,129-146.
124. Men, Y.; Audran, R.; Thomasin, C.; Eberl, G.; Demotz, S.; Merkle, H. P.; Gander, B.; Corradin, G. MHC class I- and class II-restricted processing and presentation of microencapsulated antigens. Vaccine 1999, 17, 1047-1056.
125. Prior, S.; Gander, B.; Blarer, N.; Merkle, H. P.; Subira, M. L.; Irache, J. M.; Gamazo, C. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur. J. Pharm. Sci. 2002, 15, 197-207.
126. Lunsford, L.; McKeever, U.; Eckstein, V.; Hedley, M. L. Tissue distribution and persistence in mice of plasmid DNA encapsulated in a PLGA-based microsphere delivery vehicle. J. Drug Target. 2000, 8, 39-50.
127. Jilek, S.; Merkle, H. P.; Walter, E. DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv. Drug Deliv. Rev. 2004, 57, 377-390.
128. Eyles, J. E.; Spiers, I. D.; Williamson, E. D.; O., A. H. Analysis of local and systemic immunological responses after intratracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis subunit vaccines. Vaccine 1998, 16, 2000-2009.
129. Gutierro, I.; Hernandez, R. M.; Igartua, M.; Gascon, A. R.; Pedraz, J. L. Influence of dose and immunization route on the serum IgG antibody response to BSA-loaded PLGA microspheres. Vaccine 2002, 20, 2181-2190.
130. Thomasin, C.; Corradin, G.; Men, Y.; Merkle, H. P.; Gander. Tetanus toxoid and synthetic malaria antigen containing poly(lactide)/poly(lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response. J. Control. Release 1996, 41, 131-145.
131. Alonso, M. J.; Gupta, R. K.; Min, C.; Siber, G. R.; Langer, R. Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 1994, 12, 299-306.
132. Newman, K. D.; Samuel, J.; Kwon, G. Ovalbumin peptide encapsulated in poly(d,l-lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J. Control. Release 1998, 54, 49-59.
133. Cleland, J. L.; Mac, A.; Boyd, B.; Yang, J.; Duenas, E. T.; Yeung, D.; Brooks, D.; Hsu, C.; Chu, H.; Mukku, V.; Jones, A. J. The stability of recombinant human growth hormone in poly(lactic-co-glycolic acid) (PLGA) microspheres. Pharm. Res. 1997, 14, 420-425.
134. Merkle, H. P.; Fischer, S.; Watterndorf, U.; Csaba, N.; Gander, B. Microparticles as generic platform for vaccine delivery. GPEN Conference, 2006. The University of Kansas.
135. Tamber, H.; Johansen, P.; P., M. H.; Gander, B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Deliv. Rev. 2004, 57, 357-376.
136. Hedley, M. L.; Curley, J.; Urban, R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat. Med. 1998, 4, 365-368.
137. Jones, D. H.; Corris, S.; McDonald, S.; Clegg, J. C.; Farrar, G. H. Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997, 15, 814-817.
138. Wang, D.; Robinson, D. R.; Kwon, G. S.; Samuel, J. Encapsulation of plasmid DNA in biodegradable poly(D,L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J. Control. Release 1999, 57, 9-18.
139. Singh, M.; Briones, M.; Ott, G.; O'Hagan, D. Cationic microparticles: a potent delivery system for DNA vaccines. Med. Sci. 1999.
140. Lavelle, E. C.; Jenkins, P. G.; Harris, J. E. Oral immunization of rainbow trout with antigen microencapsulated in poly(DL-lactide-co-glycolide) microparticles. Vaccine 1997, 15, 1070-1078.
141. Takahata, H.; Lavelle, E. C.; Coombes, A. G.; Davis, S. S. The distribution of protein associated with poly(DL-lactide co-glycolide) microparticles and its degradation in simulated body fluids. J. Control. Release. 1998, 50, 237-246.
142. Klipstein, F. A.; Engert, R. F.; Sherman, W. T. Peroral immunization of rats with Escherichia coli heat-labile enterotoxin delivered by microspheres. Infect. Immun. 1983, 39,1000-1003.
143. Morishita, I.; Morishita, M.; Takayama, K.; Machida, Y.; Nagai, T. Enteral insulin delivery by microspheres in 3 di^erent formulations using Eudragit L100 and S100. Int. J. Pharm. 1993, 91, 29-37.
144. Lin, S. Y.; Tzan, Y. L.; Lee, C. J.; Weng, C. N. Preparation of enteric coated microspheres of Mycoplasma hyopneumoniae vaccine with cellulose acetate phthalate: I. Formation condition and micromeritic properties. J. Microencapsul. 1991, 8, 317-325.
145. Maharaj, I.; Nairn, J. G.; Campbell, J. B. Simple rapid method for the preparation of enteric-coated microspheres. J. Pharm. Sci. 1984, 73, 39-42.
146. Guzman, M.; Molpeceres, J.; Garcia, F.; Aberturas, M. R. Preparation, characterization and in vitro drug release of poly-epsilon-caprolactone and hydroxypropyl methyl-cellulose phthalate ketoprofen loaded microspheres. J. Microencapsul. 1996, 13, 25-39.
147. Delgado, A.; Lavelle, E. C.; Hartshorne, M.; Davis, S. S. PLG microparticles stabilised using enteric coating polymers as oral vaccine delivery systems. Vaccine 1999, 17,2927-2938.
148. Borm, P. J.; Kreyling, W. Toxicological hazards of inhaled nanoparticles-potential implications for drug delivery. J. Nanosci. Nanotechnol. 2004, 4, 521-531.